GlassScriptPhysician profile
Daryl M Mcclendon
NPI 1013945948
$6,203.17
in general payments reported to CMS, 2019-2025
28 companies · $1,032 in 2025
The $1,032 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $466 · 2021: $413 · 2022: $702 · 2023: $1,262 · 2024: $1,061 · 2025: $1,032.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,355.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.95 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,105.82 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $583.14 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $363.25 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $302.81 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $287.24 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.67 | 2019-2022 | |
| Pfizer INC. | $261.75 | 2019-2025 | |
| Gilead Sciences, INC. | $257.08 | 2022-2023 | Epclusa |
| Ferring Pharmaceuticals INC. | $234.15 | 2019-2025 | Rebyota |
| Allergan, INC. | $167.50 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $146.17 | 2023 | Terlivaz |
| Genzyme Corporation | $121.73 | 2022-2025 | |
| Daiichi Sankyo INC. | $113.95 | 2019 | |
| Braintree Laboratories, INC. | $109.96 | 2019-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $103.10 | 2019-2021 | |
| Boston Scientific Corporation | $55.50 | 2024 | |
| Qol Medical, LLC | $51.27 | 2019-2020 | |
| Ardelyx, INC. | $47.39 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $46.66 | 2025 | Vegzelma |
| Lilly USA, LLC | $38.21 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $35.36 | 2021-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $33.87 | 2025 | Iqirvo |
| Amgen INC. | $31.04 | 2022 | |
| Mirum Pharmaceuticals, INC. | $27.03 | 2024 | Livmarli |
| Blueprint Medicines Corporation | $24.97 | 2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.95 | 2024 | Cyltezo |
| Merck Sharp & Dohme LLC | $18.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daryl Mcclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.